In summary, STEAP1 was dysregulated in pan-cancer tissues, and the aberrant expression of STEAP1 was more likely associated with clinicopathological features and predicted prognosis especially in adrenocortical carcinoma, breast cancer, glioma, renal cell carcinoma, lung cancer, prostate cancer, thyroid cancer, and endometrial carcinoma. Here, STEAP1 is linked to Familial prostate cancer.